検索に戻る
案件記録

COMPOSITIONS AND METHODS FOR ADMINISTERING ANESTHETICS

発明審査中
2閲覧数
27請求項 · 9 独立
§ Ⅰ

案件概要

発明者

Daniel S. Kohane; Tianjiao Ji; Christopher B. Weldon

IPC分類

A61K 9/1271A61K 9/A61K 9/107A61K 31/167A61K 31/445

CPC分類

A61K9/1271A61K9/19A61K9/1075A61K31/167A61K31/445

Compositions and methods of use related to formulations comprising anesthetics are generally described. Some embodiments are directed to compositions comprising a plurality of micelles and/or particles, and an anesthetic contained internally. These can be used to control and/or prolong the duration of IVRA while reducing the risk of systemic toxicity commonly due to administering anesthetics. The control and/or prolonged duration of IVRA may be due, at least in part, to the attachment of the sufficiently small micelles and/or particles to a biointerface (e.g., blood vessel surface) where the composition has been administered. Conventional IVRA methods commonly do not utilize potent and long-acting anesthetics (e.g., bupivacaine) due to the risks of cardiac toxicity. The compositions and methods described herein, however, provide a pathway for increased safety and efficiency of the use of such anesthetics, in certain embodiments. Resultantly, the performance (e.g., anesthetic distribution) of the micelles and/or particles internally containing an anesthetic may be comparatively better than the performance of free anesthetic, e.g., with respect to nerve blood and systematic drug distribution.

原文(中国語)

Compositions and methods of use related to formulations comprising anesthetics are generally described. Some embodiments are directed to compositions comprising a plurality of micelles and/or particles, and an anesthetic contained internally. These can be used to control and/or prolong the duration of IVRA while reducing the risk of systemic toxicity commonly due to administering anesthetics. The control and/or prolonged duration of IVRA may be due, at least in part, to the attachment of the sufficiently small micelles and/or particles to a biointerface (e.g., blood vessel surface) where the composition has been administered. Conventional IVRA methods commonly do not utilize potent and long-acting anesthetics (e.g., bupivacaine) due to the risks of cardiac toxicity. The compositions and methods described herein, however, provide a pathway for increased safety and efficiency of the use of such anesthetics, in certain embodiments. Resultantly, the performance (e.g., anesthetic distribution) of the micelles and/or particles internally containing an anesthetic may be comparatively better than the performance of free anesthetic, e.g., with respect to nerve blood and systematic drug distribution.

外部リソース